BG105445A - Фармацевтични агенти за лечение на болестта на паркинсон, adhd и микроаденоми - Google Patents

Фармацевтични агенти за лечение на болестта на паркинсон, adhd и микроаденоми

Info

Publication number
BG105445A
BG105445A BG105445A BG10544501A BG105445A BG 105445 A BG105445 A BG 105445A BG 105445 A BG105445 A BG 105445A BG 10544501 A BG10544501 A BG 10544501A BG 105445 A BG105445 A BG 105445A
Authority
BG
Bulgaria
Prior art keywords
microadenomas
parkinson
disease
treatment
phermaceutical
Prior art date
Application number
BG105445A
Other languages
English (en)
Inventor
Elisa JACKSON
Stafford Mclean
Stevin ZORN
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG105445A publication Critical patent/BG105445A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до използването на някои пиридо[1,2]-пиразинови производни и бис-азабициклични съединения за лечение на болестта на Паркинсон, на разстройства, свързани с дефицита на хиперактивното внимание (ADHD), и на микроаденоми при бозайници, както и до сродни състави.
BG105445A 1998-09-21 2001-04-13 Фармацевтични агенти за лечение на болестта на паркинсон, adhd и микроаденоми BG105445A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Publications (1)

Publication Number Publication Date
BG105445A true BG105445A (bg) 2001-12-29

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105445A BG105445A (bg) 1998-09-21 2001-04-13 Фармацевтични агенти за лечение на болестта на паркинсон, adhd и микроаденоми

Country Status (38)

Country Link
US (2) US6300329B1 (bg)
EP (1) EP1115402A1 (bg)
JP (1) JP2002526448A (bg)
KR (3) KR20030088512A (bg)
CN (1) CN1319013A (bg)
AP (1) AP1456A (bg)
AR (1) AR029739A1 (bg)
AU (1) AU760230B2 (bg)
BG (1) BG105445A (bg)
BR (1) BR9913975A (bg)
CA (1) CA2344670A1 (bg)
CO (1) CO5140075A1 (bg)
CZ (1) CZ20011006A3 (bg)
DZ (1) DZ2894A1 (bg)
EA (2) EA200100204A1 (bg)
EE (1) EE200100179A (bg)
GE (1) GEP20033081B (bg)
GT (1) GT199900154A (bg)
HN (1) HN1999000146A (bg)
HR (1) HRP20010209A2 (bg)
HU (1) HUP0103691A3 (bg)
ID (1) ID28028A (bg)
IL (2) IL164839A0 (bg)
IS (1) IS5852A (bg)
MA (1) MA26690A1 (bg)
MY (1) MY127939A (bg)
NO (1) NO20011409L (bg)
NZ (1) NZ509855A (bg)
OA (1) OA11653A (bg)
PA (1) PA8482001A1 (bg)
PE (1) PE20001084A1 (bg)
PL (1) PL346904A1 (bg)
SK (1) SK3592001A3 (bg)
TN (1) TNSN99177A1 (bg)
TR (2) TR200402083T2 (bg)
TW (1) TW518225B (bg)
WO (1) WO2000016777A1 (bg)
YU (1) YU21701A (bg)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AU2002315336A1 (en) * 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
DE69523155T2 (de) * 1994-06-14 2002-02-07 Pfizer Inc., New York Benzimidazolonderivate mit zentraler dopaminerger aktivität
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
OA11653A (en) 2004-12-08
EP1115402A1 (en) 2001-07-18
KR20010075222A (ko) 2001-08-09
GT199900154A (es) 2001-03-06
MA26690A1 (fr) 2004-12-20
EA200301063A1 (ru) 2004-12-30
YU21701A (sh) 2004-07-15
US6608064B2 (en) 2003-08-19
US6300329B1 (en) 2001-10-09
ID28028A (id) 2001-05-03
HN1999000146A (es) 2000-11-11
SK3592001A3 (en) 2001-12-03
BR9913975A (pt) 2001-06-19
HUP0103691A3 (en) 2003-01-28
TW518225B (en) 2003-01-21
CZ20011006A3 (cs) 2001-09-12
JP2002526448A (ja) 2002-08-20
TNSN99177A1 (fr) 2005-11-10
AU760230B2 (en) 2003-05-08
TR200101357T2 (tr) 2001-08-21
DZ2894A1 (fr) 2003-12-15
IS5852A (is) 2001-02-20
AU5383199A (en) 2000-04-10
KR20030088512A (ko) 2003-11-19
CA2344670A1 (en) 2000-03-30
MY127939A (en) 2007-01-31
KR100468340B1 (ko) 2005-01-27
CN1319013A (zh) 2001-10-24
HRP20010209A2 (en) 2002-04-30
NZ509855A (en) 2003-04-29
EE200100179A (et) 2002-10-15
PL346904A1 (en) 2002-03-11
PA8482001A1 (es) 2000-05-24
KR20040054752A (ko) 2004-06-25
IL141507A0 (en) 2002-03-10
IL164839A0 (en) 2005-12-18
HUP0103691A2 (hu) 2002-02-28
TR200402083T2 (tr) 2004-10-21
EA200100204A1 (ru) 2001-08-27
AR029739A1 (es) 2003-07-16
NO20011409D0 (no) 2001-03-20
WO2000016777A1 (en) 2000-03-30
AP1456A (en) 2005-09-30
GEP20033081B (en) 2003-10-27
CO5140075A1 (es) 2002-03-22
PE20001084A1 (es) 2000-10-18
NO20011409L (no) 2001-03-28
US20010034347A1 (en) 2001-10-25
AP2001002102A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
BG105445A (bg) Фармацевтични агенти за лечение на болестта на паркинсон, adhd и микроаденоми
TR200003011T2 (tr) Yeni dihidropirimidinler.
TR200000197T2 (tr) Yeni bileşimler
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
DE69710490D1 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
MY121294A (en) Novel hexanoic acid derivatives.
MX2007011903A (es) Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90.
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
PL338181A1 (en) Novel chemical compounds
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
TR200103237T2 (tr) İmidazodiazepin türevi
AU2278700A (en) Novel azabicyclo derivatives and their use
DE60111553D1 (de) Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
ZA89159B (en) Anti-psychotic imidazobenzodiazepine
IL104657A0 (en) Benzazepine derivatives,their preparation and pharmaceutical compositions containing them
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA05013368A (es) Derivados de indolilo biciclico y metodos para su uso como agentes serotonergicos.